Autologous hematopoietic SCT (ASCT) has been investigated as salvage therapy for refractory systemic lupus erythematosus (SLE). Although immune recovery after ASCT with in vitro purging of lymphocytes has been extensively studied, little information is available about immune recovery after ASCT without in vitro purging. Therefore, we analyzed the immune recovery of a patient who successfully underwent ASCT without in vitro purging for refractory SLE. In addition to the numbers of PBL subsets, T-cell receptor rearrangement excision circles (TRECs) and the T-cell receptor repertoire diversity of both CD4 þ and CD8 þ T cells were sequentially analyzed. All SLE-related symptoms disappeared within 3 months after ASCT and the serum antidsDNA Ab became undetectable. The number of CD4 þ CD45RO þ memory T cells remained lower than that in healthy adult controls, but the number of CD4 þ CD45RA þ naı¨ve T cells showed a rapid increase after ASCT. TRECs of both CD4 þ and CD8 þ T cells were strongly suppressed before ASCT, but consistently increased after ASCT. The T-cell receptor repertoire of CD8 þ T cells was skewed before ASCT, but the diversity recovered after ASCT. ASCT with the reinfusion of a large number of autologous T cells did not impair the recovery of naive T cells or resetting of the immune system.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that may affect multiple organs, including the skin, joints, kidneys, nervous system and so on. Intensive immunosuppressive therapies, such as intermittent pulse of CY or mycophenolate mofetil, have been shown to improve the prognosis of patients with SLE. However, a subset of patients is refractory to these treatments and their clinical prognosis remains poor. Therefore, autologous hematopoietic SCT (ASCT) has been investigated as salvage therapy for refractory SLE. The procedure includes the collection of PBSCs following mobilization with CY and G-CSF, an immunoablative conditioning regimen using high-dose chemotherapy with or without antithymocyte globulin/antilymphocyte globulin (ALG), and the infusion of autologous PBSC with or without in vitro purging of lymphocytes. A single-center study by Burt et al. showed a 5-year overall survival of 84% and a 5-year disease-free survival of 50% after ASCT for patients with severe and treatment-refractory SLE. 1 The European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Disease analyzed all first ASCT for autoimmune diseases reported to the EBMT registry between 1996 and 2007. 2 Of the 900 patients analyzed, 85 had SLE and their 5-year progression-free survival was 44%. However, the procedure for ASCT significantly varied among centers. For example, antithymocyte globulin/ALG was used in 55% of patients, and intensive conditioning regimens, including TBI or BU, were applied in 10%. Especially, in vitro purging of lymphocytes was performed in 44% of patients. This strategy is based on the concept that the reinfusion of autologous lymphocytes may lead to the relapse of autoimmune disease. However, in vitro purging may also strongly affect the immune recovery after ASCT, whereas its impact on disease relapse remains unclear. 2 The delayed immune recovery after ASCT for autoimmune disease has been associated with infectious complications. 3 Although immune recovery after ASCT with in vitro purging has been extensively studied, 4,5 little information is available about immune recovery after ASCT without in vitro purging. Therefore, in this study, we analyzed the immune recovery of a patient who successfully underwent ASCT without in vitro purging for refractory SLE.
Materials and methods

Cell preparation
PBMCs were isolated from peripheral blood by Ficollhypaque density centrifugation. CD4 þ and CD8 þ T cells were purified using the MACS magnetic bead separation system (Miltenyi Biotec, Auburn, CA, USA).
T-cell receptor rearrangement excision circle quantification T-cell receptor rearrangement excision circles (TRECs) were quantified in purified CD4 þ and CD8 þ T cells by real-time quantitative PCR with the 5 0 -nuclease (TaqMan) assay and an ABI7900 system (Life Technologies, Foster City, CA, USA) as described elsewhere. 6 Briefly, cells were lysed in 100 mg/mL proteinase K for 1 h at 56 1C, followed by 10 min at 95 1C at 107 cells/mL. Next, real-time quantitative PCR was carried out on 2.5 mL cell lysate under the following conditions: 50 1C for 2 min, followed by 95 1C for 10 min, and finally 40 cycles of amplification (95 1C for 15 s and 60 1C for 1 min). The sequences of the primers and probe were as follows: forward primer 5 0 -CAC ATCCCTTTCAACCATGCT-3 0 , reverse primer 5 0 -GCCA GCTGCAGGGTTTAGG-3 0 , and the probe 5 0 -FAM-ACA CCTCTGGTTTTTGTAAAGGTGCCCACT-TAMRA-3 0 . A standard curve was plotted, and TREC values for samples were calculated by ABI PRISM 7900 software. Cell lysates were checked for the consistency of DNA content by an internal control gene. The mean copy numbers of TRECs in 10 5 CD4 þ and CD8 þ T cells from 10 healthy adults were 1440 ± 880 and 1920 ± 1300, respectively.
T-cell receptor repertoire analysis T-cell receptor repertoire analysis has been described elsewhere. 7 Briefly, total RNA was purified by a QIAamp RNA blood Mini Kit (Qiagen, GmbH Germany). The RNA was then reverse transcribed into cDNA using random primers and SuperScript II reverse transcriptase (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. cDNA was PCR amplified under the following conditions: 95 1C for 10 min, followed by 35 cycles (94 1C for 1 min, 55 1C for 1 min and 72 1C for 1 min) with a primer specific to 24 different BV subfamilies (BVs 1-203 and BVs 21-244) and a fluorescent BC primer. 8, 9 In all, 1 mL of amplified products was mixed with 20 mL HiDi formamide and 0.5 mL GS500 ROX size standard, and the mixture was electrophoresed by an ABI 3100 system. Data were analyzed with GeneMapper software (Life Technologies).
The overall complexity within a Vb subfamily was determined by counting the number of discrete peaks and determining their relative size on the electropherogram by a complexity scoring system as described elsewhere. 10 Complexity score ¼ (total peak area/sum of the major peak areas) Â (number of major peaks). Major peaks were defined as peaks whose area was at least 10% of the total peak area.
The mean complexity scores of CD4 þ and CD8 þ T cells from 10 healthy adults were 116.1±2.36 and 109.49 ± 6.77, respectively.
Case report
A 19-year-old female developed oral ulcers, polyarthritis and a butterfly-like rash. She was diagnosed to have SLE. Her symptoms, including high fever, rash, oral mucositis and polyarticular joint pain, showed only transient improvement in response to various treatments including high-dose steroids (that is, betamethasone pulse at 100 mg/ day for 3 days), CYA (150 mg/day), tacrolimus (4 mg/day), pulsed CY (500-800 mg for eight times), rituximab (500 mg twice), high-dose i.v. gammaglobulin and plasma exchange during the clinical course of B4 years. She also developed lupus nephritis and central nervous system manifestations. Therefore, we planned ASCT after approval by the ethics committee and after obtaining written informed consent from the patient.
At this time, she was 22 years old. She had persistent fever between 37.5 and 39 1C, a butterfly-like rash and oral mucosal ulcers. Articular pain was observed at the elbow, wrist, hip, knee and ankle. The WBC count was 7.97 Â 10 9 /L with 85% neutrophils and 14% lymphocytes. The hemoglobin level was 8.7 g/dL and the platelet count was 466 Â 10 9 /L. The serum anti-dsDNA IgG Ab was detected at 413 U/mL (normal range: o10 U/mL). Serum complement levels of C3 and C4 were decreased to 70 mg/dL (normal range: 65-135 mg/dL) and 8 mg/dL (normal range 13-35 mg/dL), respectively. She required oral betamethasone at 7.5 mg/day to alleviate these symptoms.
PBSCs were mobilized with the administration of CY at 2 g/m 2 followed by G-CSF (filgrastim at 600 mg/day). A sufficient number of CD34 þ cells was obtained by apheresis and cryopreserved without graft manipulation. The conditioning regimen before ASCT included the i.v. administration of CY at 50 mg/kg/day from day À6 to day À3 and rabbit ALG (Zetbulin, Fresenius, Munich, Germany) at 5 mg/kg/day from day À5 to day À2. After the infusion of autologous peripheral blood graft including CD34 þ cells at 2.27 Â 10 6 /kg and CD3 þ cells at 0.22 Â 10 8 cells/kg, G-CSF (filgrastim at 75 mg/day) was started on day 7 after ASCT. Neutrophil recovery of more than 0.5 Â 10 9 /L was observed on day 10. The dose of betamethasone was gradually decreased from 7.5 to 3 mg/ day during these procedures.
With regard to the disease activity of SLE, arthritis and butterfly erythema began to improve after we administered CY to mobilize PBSC, and thus we started tapering the dose of steroid. After ASCT, the anti-dsDNA Ab became undetectable (Figure 1a) . The SLE disease activity index 2000 (SLEDAI-2K) score was 15 before the administration of CY to mobilize PBSC, but decreased to 4 at 30 days after ASCT, and all the SLE-related symptoms disappeared (SLEDAI-2K score 0) within 3 months after ASCT.
11 She returned to nursing school and is currently in good physical condition after 2 years of ASCT. The dose of steroid is Immune recovery after autologous HSCT for refractory SLE H Wada et al being gradually tapered, and the last prescribed dose was 8 mg/day of prednisolone.
Immune recovery
The PBL count remained lower than 0.5 Â 10 9 /L in the first 6 months after ASCT, but was persistently higher than 1.0 Â 10 9 /L over the next 18 months, whereas the antidsDNA Ab level was sufficiently suppressed (Figure 1a) . The results of immunophenotypic analyses are shown in Figure 1b . The number of CD4 þ CD45RO þ memory T cells remained lower than that in the healthy adult controls (400/mL). 4 On the other hand, the number of CD4 þ CD45RA þ naı¨ve T cells showed a rapid increase between 12 and 18 months after ASCT, and became higher than that in the healthy controls (300/mL). As shown in Table 1 , TRECs of both CD4 þ and CD8 þ T cells were strongly suppressed before ASCT (156 and 356 copies/10 5 cells, respectively), but were consistently increased after ASCT. At 2 years after ASCT, TRECs of CD4 þ and CD8 þ T cells were 2602 and 1584 copies/10 5 cells, respectively, and were almost equivalent to those in healthy adults (1440 ± 880 and 1920 ± 1300, respectively).
With regard to T-cell receptor repertoire analyses, the T-cell receptor repertoire of CD4 þ T cells was diverse before ASCT (Table 1) . Repertoire skewing was observed after ASCT, but the diversity was reconstituted 1 year after ASCT. On the other hand, the T-cell receptor repertoire of CD8 þ T cells was skewed before ASCT (Figure 2a) . However, the diversity recovered 2 years after ASCT (Figure 2b ).
The number of CD4 þ CD25 þ T cells was decreased after ASCT, but recovered to the pre-ASCT level 1 year after ASCT. The kinetics of the number of CD8 þ cells was similar. We did not evaluate the expression of intracellular FoxP3, and thus the exact number of regulatory T cells was not determined. However, it has been reported that between one-and two-thirds of CD4 þ CD25 þ T cells were positive for FoxP3 in SLE patients after ASCT. 4 Therefore, the number of FoxP3 þ regulatory T cells at 1-2 years after ASCT was expected to be, at least, equivalent to that in healthy controls (65/mL). 4 The serum IgG level was 9.92 g/L before ASCT and decreased to 5.62 g/L at 7 months after ASCT, but has remained consistently higher than 10 g/L beginning 1 year after ASCT. Serum IgA and IgM levels were persistently within the normal range.
Discussion
The mechanism of action of ASCT includes not only the elimination of autoreactive effector and inflammatory cells by an immunoablative conditioning regimen but also resetting of the adaptive immune system. 12, 13 The reactivation of thymic function after ASCT was illustrated by an increase in the number of CD31 þ CD45RA þ CD4 þ T cells and the amount of TRECs.
12,13 T-cell receptor repertoire analysis revealed improved diversity after ASCT. 12, 13 In addition, the regeneration of thymic-derived FoxP3 þ regulatory T cells may contribute to the induction of immune tolerance. 4, 14 However, these analyses of immune recovery were performed in patients who underwent ASCT with in vitro purging of lymphocyte.
We did not perform in vitro purging in the current patient, as in vitro purging may delay the immune recovery after ASCT and induce infectious complications. 3 On the other hand, it is not clear whether the relapse rate after ASCT is decreased by in vitro purging. 2 This patient remains relapse free after 2 years of ASCT. Therefore, the efficacy of ASCT may not be spoiled by omitting in vitro purging, at least, in this patient, although the follow-up duration is still too short to draw definitive conclusions. With regard to immune recovery, we compared the data for this patient who received unmanipulated graft with those in seven patients who underwent ASCT with in vitro purging in the detailed immune recovery analyses by Alexander et al. 4 The number of infused CD34 þ cells was similar: 2.27 Â 10 6 cells/kg in this patient vs 2.0-6.1 Â 10 6 cells/kg in the seven patients. However, the number of infused CD3 þ cells in this patient (0.22 Â 10 but the total dose of ALG in the conditioning regimen was lower in the current patient (25 vs 90 mg/kg). This difference might have also affected the immune recovery after ASCT, as ALG administered before ASCT depletes T cells not only in the patient but also in the infused graft.
The recovery of CD4 þ CD45RO þ memory T cells was similar, but that of CD4 þ CD45RA þ naı¨ve T cells in this patient was faster than that in the previous study (median of 503 vs 244/mL at 2 years after ASCT). The significant recovery of TRECs might contribute to the fast reconstitution of naı¨ve T cells. In addition, T-cell receptor repertoire diversity of CD8 þ T cells was improved after ASCT, although the diversity of CD4 þ T cells was not impaired even before ASCT. Such reconstitution of the juvenile immune system may have contributed to the reestablishment of tolerance.
In conclusion, in this single patient, ASCT with the reinfusion of a large number of autologous T cells by omitting in vitro purging did not impair the recovery of naive T cells or resetting of the immune system compared with ASCT with in vitro purging. Infused T cells might have prevented severe infectious complications early after ASCT. The present patient is in clinical remission after 2 years of ASCT. However, a larger study is required to confirm the benefit of ASCT without in vitro purging.
